Tumor vascular disrupting agent 5,6‐dimethylxanthenone‐4‐acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase
Tumor vascular disrupting agent 5,6‐dimethylxanthenone‐4‐acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase
复制标题
DOI：
10.1111/jth.12362
复制
发表时间：
2013-10
影响因子：
10.4
通讯作者：
Shenghui Zhang;Yan Zhang;J. Shen;Si Zhang;L. Chen;J. Gu;J. Mruk;G. Cheng;L. Zhu;S. Kunapuli;Zhongren Ding
中科院分区：
文献类型：
--
作者：
Shenghui Zhang;Yan Zhang;J. Shen;Si Zhang;L. Chen;J. Gu;J. Mruk;G. Cheng;L. Zhu;S. Kunapuli;Zhongren Ding
5，6-二甲基黄原酮-4-乙酸(DMXAA)是一种正在进行临床试验的肿瘤血管干扰剂，是一种邻近的抗肿瘤药物。DMXAA在结构上与黄酮8-醋酸(FAA)相似，FAA是一种古老的肿瘤血管干扰剂，具有抗血小板和抗血栓作用。与会导致肿瘤患者出血的FAA相比，接受DMXAA治疗的患者没有出血的报道。DMXAA是否也影响血小板功能尚不清楚。
5,6‐Dimethylxanthenone‐4‐acetic acid (DMXAA) is a tumor vascular disrupting agent under clinical trials as an adjacent antitumor agent. DMXAA is structurally similar to flavone‐8‐acetic acid (FAA), an old tumor vascular disrupting agent with antiplatelet and antithrombotic effects. In contrast to FAA, which causes bleeding in tumor patients, no bleeding has been reported in patients receiving DMXAA. Whether DMXAA also affects platelet function is not clear.